https://scholars.lib.ntu.edu.tw/handle/123456789/336687
標題: | How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: A national population-based study | 作者: | Sun, Y. Lai, MS. Lu, CJ. Chen, RC |
關鍵字: | Alzheimer's dementia; Cholinesterase inhibitor; Treatment duration | 公開日期: | 2008 | 卷: | 15 | 期: | 3 | 起(迄)頁: | 278-283 | 來源出版物: | European Journal of Neurology | 摘要: | The aims of this study were to evaluate the duration of acetylcholinesterase inhibitors (AChEI) utilization as well as the patients' cognition maintenance. This study was using panel data from the Bureau of National Health Insurance (BNHI) of Taiwan from 2001 to 2004. Patients with mild or moderate AD were prescribed AChEI (donepezil, rivastigmine, or galantamine). By the regulation of BNHI, if the score of Mini-Mental Status Examination worsened by more than two points or clinical dementia rating (CDR) worsened by one or more grades in the follow-up every half year, the AChEI treatment would be terminated. Kaplan-Meier product-limit method was used to estimate duration of drug utilization. Regression model was performed to analyse the factors affecting the discontinuation of AChEI treatment. Our results showed female are more and younger than male in mild to moderate Alzheimer's dementia. The mean duration of use of AChEI was 432 days. Only 9.6% of patients maintained stable cognition tests results with continued drug refill for more than 3 years. Discontinuation rate in older patients (age ?76 years) was higher than those in younger age (P = 0.0009). The average duration for AChEI therapy is around 14 months. The elderly are at high risk for treatment discontinuation. ? 2008 The Authors. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-39149121173&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/336687 |
DOI: | 10.1111/j.1468-1331.2007.02049.x | SDG/關鍵字: | cholinesterase inhibitor; donepezil; galantamine; rivastigmine; aged; Alzheimer disease; article; cognition; controlled study; disease exacerbation; drug utilization; drug withdrawal; female; follow up; health insurance; high risk behavior; human; Kaplan Meier method; maintenance therapy; major clinical study; male; mental health; population research; priority journal; regression analysis; statistical significance; treatment duration; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Community Health Planning; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Proportional Hazards Models; Psychiatric Status Rating Scales; Taiwan; Time Factors |
顯示於: | 流行病學與預防醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。